Careers

Together, we can
accomplish more.

If you’re patient focused, passionate about what you do, and have an entrepenuerial spirit, you might be interested in learning more about working with us.

Explore Renibus’ career opportunities:

Join Our Team

Director/ Senior Director, Global Program Management

The Director/ Senior Director, Global Program Management at Renibus Therapeutics will play a critical role in overseeing programs from preclinical to Phase 3 and NDA filing. Together with program and functional leaders, this individual will drive the creation, development, implementation and tracking of global, integrated cross-functional project plans in alignment with their program strategies. This role will provide an independent perspective to the overall project strategy and drive decision making to ensure efficient program execution. In addition to timelines, they will be accountable for the tracking of program costs, as well as risk assessment and mitigation. This is an opportunity for a versatile individual to help establish the program management function as a key value driver for Renibus Therapeutics.

Apply Now

Responsibilities:

  • Create and maintain a cross-functional development plan, timeline and budget for each assigned program, ensuring progress vs. plan. This includes identifying and managing critical path activities.
  • Support and facilitate effective, science-based business decisions including development of scenarios as needed, highlighting interdependencies and downstream impacts
  • Develop a risk management plan
  • Accountable for communication to team and stakeholders in a transparent and timely manner.
  • Coordinate budget planning across functions and support finance in highlighting budgetary gaps
  • Support and foster a high performing team and monitor the health and operating efficiency of the team as a unit.
  • Set up and manage systems/ processes in the Program Management Office (PMO) as needed. Makes sure there is consistency across programs and focuses on continuous improvement.

Education/Knowledge/Skills/Abilities Required:

  • Advanced degree in Life Sciences, Chemical Sciences, Physical Sciences or other relevant discipline preferred.
  • Minimum of 12 years of experience in biotech/pharmaceutical industry, including at least 6 years in project/portfolio management with experience leading cross-functional matrix teams
  • Demonstrated competency and expertise in Clinical Drug Development and/or CMC with solid understanding of drug development and the ability to contribute to strategic discussions.
  • Excellent Project Management Skills required– drives execution while balancing speed, quality, and cost.
  • Leadership skills including situational leadership, ability to lead a team of experts and influence without authority.
  • Demonstrated ability to lead matrix teams, knows how to work at the strategic level and when to delve deeper to resolve issues and challenges.
  • Strong communicator able to integrate and succinctly summarize the various parts of a project and effectively tailor messages to audience incl. senior leaders.
  • Development of high-quality documents and presentations for review at governance committees and support senior management in preparation documents and presentations as needed. Demonstrated ability to lead multiple programs and initiatives and to prioritize tasks.
  • Experience setting and tracking cross-functional program budgets.
  • Experience with commonly used project management tools.

About Renibus Therapeutics

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases. The Company has developed a robust portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning. Renibus’ first-in-class lead program, RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of Nrf2, IL-10, and ferritin. RBT-1 (stannic protoporfin/iron sucrose) is currently in Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery. RBT-2 is an antioxidant and anti-fibrotic drug that has been shown to reduce the risk of CKD progression in preclinical models and will be in IND enabling and clinical development in 2023. RBT-3, a novel, low molecular weight iron nanoparticle, is one component of RBT-1 (stannic protoporfin/iron sucrose) and is targeted at reducing the risk of cisplatin-induced nephrotoxicity and will be taken into clinical development in 2023. RBT-9 (stannic protoporfin) is a potent anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties. It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. Treatment with RBT-9 showed a statistically significant improvement in clinical status by 7 days (p<0.05) as well as a statistically significant reduction in hospital length of stay (-7.9 days, p<0.05). Additional pre-clinical work is underway to help inform the clinical development strategy.

Submit Your Resume

"*" indicates required fields

Max. file size: 50 MB.